Page 42 - Kodiak Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article PALO ALTO, Calif., Feb. 2, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a presentation of clinical study data on its investigational therapy KSI-301 will be made at the upcoming Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition meeting. Details of the presentation are as follows: Title: KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstr...

Share: Kodiak Sciences (NASDAQ: KOD) shares are trading lower after BMO Capital downgraded the stock from Outperform to Market Perform. Kodiak Sciences is a clinical stage company. It is engaged in developing innovative therapeutics to treat high prevalence of ophthalmic diseases. The most advanced product candidate of the group is KSI-301, a biologic therapy built with antibody biopolymer conjugate platform, which is designed to maintain potent and effective drug levels in ocular tissue. Kodiak Sciences shares traded down 4.60% to $156.78 The stock has a 52-week high of $169.98 and a 52-week...

The Fifth Annual Retina Fellow Summit This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. 2.00 CME Activity Expiration Date: 12/31/2021 Activity Overview This activity features highlights captured from the Fifth Annual Retina Fellow Summit held in November 2020. The Summit included an expert faculty panel and an audience of retina fellows engaging in discussions on current clinical data, clinical cases, and practice transitions. The overall goal of this program is to provide retina fellows, ophthalmology residents, retina ...

Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months. It likely is safe to say no professionals in drug development and manufacturing has a reliable crystal ball that can provide a crystal-clear picture of exactly what will happen in the coming 12 months. However, seasoned and savvy professionals can offer educated opinions, and advice on preparing for what might lie ahead. To get a clearer perspective on what 2021 might have in store for the pharma field, Outsourci...

IPO Alert: AbCellera Biologics (ABCL) WASHINGTON (dpa-AFX) - AbCellera Biologics is scheduled to make its debut on the Nasdaq Global Select Market today (December 11), under the ticker symbol 'ABCL.' The Vancouver, Canada-based AbCellera Biologics is a technology company with an antibody discovery platform that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat diseases. The company has offered to sell 24.15 million shares of its common stock at a price of $20 each. The underwriters have an option for a period of 30 days to pu...